<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719407</url>
  </required_header>
  <id_info>
    <org_study_id>H9299-32566-01</org_study_id>
    <secondary_id>Thrasher 02827-0</secondary_id>
    <nct_id>NCT00719407</nct_id>
  </id_info>
  <brief_title>Neonatal Erythropoietin in Asphyxiated Term Newborns</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Neonatal Erythropoietin in Asphyxiated Term Newborns: a Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Santa Clara Valley Health &amp; Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and pharmacokinetics of moderate to high
      doses of erythropoietin in newborn infants with birth asphyxia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Newborn infants with birth asphyxia are at high risk of death or long-term neurologic
      disability; yet therapies for birth asphyxia are currently limited. Erythropoietin (Epo) is a
      FDA-approved drug that is an effective neuroprotective agent in animal models of birth
      asphyxia. This is a phase I dose finding multi-center trial that will test the safety and
      pharmacokinetics of Epo in human infants with birth asphyxia. The long-term objectives of the
      proposed research are to reduce mortality and to decrease the risk of long-term disabilities
      in infants who survive beyond the newborn period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious adverse event</measure>
    <time_frame>14 days of life</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>1 to 11 days of life</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypoxic-ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will be in this single arm, who will receive experimental drug treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <description>250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Procrit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. â‰¥ 36 weeks gestational age

          2. Perinatal depression (low Apgar score, need for resuscitation)

          3. Moderate to severe encephalopathy

        Exclusion Criteria:

          1. Specific aEEG findings

          2. Intrauterine growth restriction

          3. Severe congenital anomaly, genetic syndrome, metabolic disorder, arthrogryposis, TORCH
             infection

          4. Microcephaly

          5. Infant older than 23.5 hours of age at the time of consent

          6. Infant judged by an attending physician to be likely to die due to the severity of
             illness

          7. Polycythemia

          8. Hypertension

          9. No in-dwelling line
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne W Wu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <last_update_submitted>November 7, 2012</last_update_submitted>
  <last_update_submitted_qc>November 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Yvonne Wu</investigator_full_name>
    <investigator_title>Professor of Neurology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>birth asphyxia</keyword>
  <keyword>neonatal encephalopathy</keyword>
  <keyword>hypoxic-ischemic encephalopathy</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

